 The clinical and biological tolerance of resveratrol in HD patients will be evaluated by i neuropsychiatric questionnaires: Starkstein apathy scale, Hospital Anxiety and Depression Scale HADS, Systems Behaviour Inventory FrSBe and SF36, ii a cognitive test; Symbol Digit Modalities Test SDMT and iii routine biochemical tests The clinical benefit of resveratrol will be evaluated by a decrease in the progression of the UHDRS over a year of treatment The benefit of resveratrol on brain energy metabolism will be evaluated by the restoration of an increased ratio of inorganic phosphatephosphocreatine - reflecting normal brain activation - during visual stimulation, using 31P-MRS as we described The progression of caudate atrophy over a year will be correlated with the changes in brain energy profile as well as changes in the progression of the UHDRS. 